Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.ACGN · Entity 110652 | CHIEF FINANCIAL OFFICER | January 20, 2023 | February 02, 2023 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Interim CFO | August 18, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date January 20, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2033-01-20 | Direct | 25,400 |
Reported balance
After 2023-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 25,400 · Balance 25,400 F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
Verrica Pharmaceuticals Inc.
Report date August 18, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,962 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Purchase · Acquired 5,000 · Balance 23,962 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 18, 2026 21:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 5,000 | $4.93 | $24,650.00 |
DisclosureSEC source: 0001556327-26-000003 · form4-08182026_050806.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,962 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 13:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001556327-25-000006 · form4-12302025_081201.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,962 F1 · shares: Represents a fully vested restricted stock unit award. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 00:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseSeries C Warrant (right to buy) · Derivative | 884 | Not disclosed Strike: $6.32 | Not disclosed |
DisclosureSEC source: 0001556327-25-000004 · form4-11252025_071111.xml · derivative · entry 2 Kirby John J. · CIK 0001556327 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 884 Underlying: Common Stock · 884 shares Expires 2030-11-25 F3 · price: The reported securities are included within 3,536 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 00:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 3,536 | $4.24 | $15,001.48 |
DisclosureSEC source: 0001556327-25-000004 · form4-11252025_071111.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,962 F1 · balance_after: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. Read SEC document |
| November 06, 2024 Filed Nov 7, 2024 02:04 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 54,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026290 · form4-11072024_021129.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,267 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest vest in full on May 4, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 20, 2023 Filed Feb 2, 2023 20:15 UTC | Aceragen, Inc. ACGN · Entity 110652 | GrantStock Options (Right to Buy) · Derivative | 25,400 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001415889-23-001859 · form4-02032023_010245.xml · derivative · entry 1 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 Underlying: Common Stock · 25,400 shares Expires 2033-01-20 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:15 UTC | Aceragen, Inc. IDRA · Entity 110652 | Tax withholdingCommon Stock | 119,957 | $0.71 | $85,157.47 |
DisclosureSEC source: 0001415889-23-000764 · form4-01112023_020116.xml · nonDerivative · entry 2 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,893 F2 · shares: Represents the number of shares withheld by Issuer to cover tax obligations in connection with the grant of the shares of common stock. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:15 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 399,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000764 · form4-01112023_020116.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,850 F1 · shares: Represents shares of common stock granted under the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan, as amended and restated. The shares were granted pursuant to that certain Employment Continuation and Retention Bonus Letter Agreement, dated as of September 28, 2022, between the Issuer and Reporting Person. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 17:27 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 66,500 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001415889-22-007540 · form4-07072022_020708.xml · derivative · entry 1 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2032-07-06 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on July 6, 2026, with 25% vesting on July 6, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 17:45 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 41,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001415889-22-003753 · form4-04042022_020415.xml · derivative · entry 1 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires 2032-04-01 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 20:41 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-22-000791 · form4-01262022_050107.xml · derivative · entry 1 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 16:16 UTC | Aceragen, Inc. IDRA · Entity 110652 | PurchaseCommon Stock | 10,000 | $0.62 | $6,150.00 |
DisclosureSEC source: 0001415889-21-006155 · form4-12212021_041212.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,632 Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 16:05 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 66,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001415889-21-003584 · form4-07122021_040701.xml · derivative · entry 1 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2031-07-08 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 16:05 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 6,250 | $1.42 | $8,875.63 |
DisclosureSEC source: 0001415889-21-001670 · form4-03292021_010319.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,632 F1 · shares: Restricted Stock Units ("RSUs") granted to Reporting Person on January 3, 2019 and January 10, 2020 were accelerated and became fully vested on March 23, 2021. The amount reported in Column 4 represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 20,125 RSUs on March 23, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 12, 2021 Filed Jan 12, 2021 19:12 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 1,693 | $4.22 | $7,151.74 |
DisclosureSEC source: 0001179110-21-000563 · edgar.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,882 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 5,000 Restricted Stock Units ("RSUs") on January 10, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from 4.205 to $4.232 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the reported securities beneficially owned, 20,125 shares are represented by unvested RSUs. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 19:12 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001179110-21-000563 · edgar.xml · derivative · entry 2 Kirby John J. · CIK 0001556327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2031-01-08 F4 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 17:04 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 862 | $3.90 | $3,361.80 |
DisclosureSEC source: 0001179110-21-000338 · edgar.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,575 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 2,563 Restricted Stock Units ("RSUs") on January 3, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Of the reported securities beneficially owned, 25,125 shares are represented by unvested RSUs. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 16:36 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001179110-20-008429 · edgar.xml · derivative · entry 1 Kirby John J. · CIK 0001556327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-07-21 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 21, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 21, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 18:32 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001179110-20-000563 · edgar.xml · derivative · entry 2 Kirby John J. · CIK 0001556327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-10 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 10, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 18:32 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000563 · edgar.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,437 F1 · shares: Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award. F2 · balance_after: Securities beneficially owned totaling 36,437 includes 8,749 shares of Issuer common stock owned and 27,688 of unvested RSU's held by the reporting person. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 08:11 UTC | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 911 | $1.78 | $1,621.94 |
DisclosureSEC source: 0001179110-20-000448 · edgar.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,437 F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 2,562 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the reported shares, 7,688 shares are represented by unvested RSUs. Read SEC document |
| January 07, 2020 Filed Jan 14, 2020 18:07 UTC Amendment | Aceragen, Inc. IDRA · Entity 110652 | SaleCommon Stock | 911 | $1.78 | $1,621.94 |
DisclosureSEC source: 0001179110-20-000557 · edgar.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,437 F1 · deemedExecutionDate: The Form 4 filed on January 10, 2020 did not include the Deemed Execution Date in Column 2A and corresponding footnote disclosure. This amendment to the Form 4 is being filed to include this information for the reported transaction. F2 · deemedExecutionDate: In accordance with terms of the RSU agreement, the "sell to cover" provision is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act. F3 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 2,562 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · balance_after: Of the reported shares, 7,688 shares are represented by unvested RSUs. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 17:18 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001179110-19-008597 · edgar.xml · derivative · entry 1 Kirby John J. · CIK 0001556327 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2029-07-09 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 9, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 9, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:17 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option (Right to Buy) · Derivative | 25,600 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001179110-19-000530 · edgar.xml · derivative · entry 2 Kirby John J. · CIK 0001556327 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2029-01-03 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 3, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:17 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantCommon Stock | 10,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000530 · edgar.xml · nonDerivative · entry 1 Kirby John J. · CIK 0001556327 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,509 F1 · shares: Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award. F2 · balance_after: Securities beneficially owned totaling 12,509 includes 2,259 shares of Issuer common stock owned and 10,250 of unvested RSU's held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.